Human CCL5/RANTES Quantikine ELISA Kit

Product Details

Reactivity HuSpecies Glossary
Applications ELISA

Order Details

View Available Conjugates
Catalog# & Conjugate Size Price

Human CCL5/RANTES Quantikine ELISA Kit Summary

The Quantikine Human RANTES Immunoassay is a 3.5 hour solid phase ELISA designed to measure human RANTES levels in cell culture supernates, serum, plasma, and urine. It contains E. coli-derived recombinant human RANTES and antibodies raised against the recombinant factor. This immunoassay has been shown to accurately quantitate the recombinant factor. Results obtained using natural ...human RANTES showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values of natural human RANTES.
Show More
Natural and recombinant human RANTES
See PDF Datasheet for details
See PDF Datasheet for details
Spike Recovery
See PDF Datasheet for details
Sample Volume
See PDF Datasheet for details


Application Notes
No significant interference observed with available related molecules.
Read Publications using DRN00B.

Packaging, Storage & Formulations

Store the unopened product at 2 - 8 °C. Do not use past expiration date.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human CCL5/RANTES Quantikine ELISA Kit

  • CCL5
  • chemokine (C-C motif) ligand 5
  • D17S136Enormally T-expressed, and presumably secreted
  • EoCP
  • Eosinophil chemotactic cytokine
  • SISd
  • SIS-delta
  • small inducible cytokine A5 (RANTES)
  • small inducible cytokine subfamily A (Cys-Cys), member 5
  • Small-inducible cytokine A5
  • T cell-specific protein P228
  • T-cell specific protein p288
  • TCP228T-cell-specific protein RANTES


RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), also known as CCL5, is a member of the "CC" subfamily of chemokines. It plays a primary role in the inflammatory immune response via its ability to chemoattract leukocytes and modulate their function. The cDNA for RANTES was initially discovered by subtractive hybridization as a T cell specific sequence (1, 2). Human RANTES cDNA encodes a highly basic 91 amino acid (aa) residue precursor polypeptide with a 23 aa hydrophobic signal peptide that is cleaved to generate the 68 aa mature protein (1, 2). Human RANTES exhibits approximately 85% homology with mouse RANTES at the deduced aa level (3, 4). 
RANTES is a potent chemoattractant for a number of different cell types including unstimulated CD4+/CD45RO+ memory T cells and stimulated CD4+ and CD8+ T cells with naive and memory phenotypes, NK cells, basophils, eosinophils, dendritic cells, mast cells, monocytes, and microglia (5-13). In addition to its effects on migration, RANTES can activate a number of cell types including T cells (14-16), monocytes (17), neutrophils (17), NK cells (7), dendritic cells (18), and astrocytes (19). T cell activation generally requires relatively high RANTES concentrations (~ 1 μM) and is dependent upon aggregation of the molecule and association with cell surface glycosaminoglycans (GAGs) (15-17). Whether this activity occurs in vivo remains unclear although in mice, intraperitoneally injected RANTES mutants that are unable to aggregate and/or bind GAG, are not capable of attracting leukocytes when compared to wild-type controls (20). Other in vivo studies show that RANTES knockout mice exhibit deficient recruitment of leukocytes to sites of acute inflammation (21). 
RANTES, is known to interact with four identified seven transmembrane G-protein coupled receptors: CCR1, CCR3, CCR4, and CCR5 (22-25). RANTES stimulation can initiate a variety of signaling cascades that are cell context dependent. For instance, in T-cells, RANTES can stimulate elevations of intracellular Ca2+ (26), and activation of focal adhesion kinase (FAK) (27), protein kinase A (28), PI3-kinase (14), Rho GTPase (29), and JAK/STAT signaling pathways (30). The cytomegalovirus protein US28 exhibits significant homology with CC chemokine receptors and is capable of binding RANTES (31). Membrane-spanning US28 can, depending on the context, signal in a constitutive manner (32), bind RANTES and initiate G-protein-mediated signaling cascades (33), or sequester RANTES and potentially alter inflammatory responses (34-36). 
The RANTES receptor CCR5 is also the primary co-receptor for R5 (M-tropic) variants of HIV-1 (37, 38). It has been demonstrated that RANTES, as well as the other CCR5 ligands, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta , can competitively inhibit CCR5/HIV-1 interaction and suppress viral infection in vitro (39, 40). These effects apparently do not require fully intact signaling from the CCR5 receptor (41). Consequently, modified forms of RANTES and non-peptide compounds that block the interaction of HIV-1 with CCR5 show promise for future therapies (41-44). In contrast, several reports show that RANTES can enhance in vitro replication of X4 (T-tropic) variants of HIV-1 that use CXCR4 as a co-receptor rather than CCR5 (45, 46). This activity usually requires relatively high RANTES concentrations (~μM) and is dependent upon interaction with cell surface GAGs, oligomerization, and activation of tyrosine kinase and MAP kinase signaling cascades (46, 47).
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to

Publications for CCL5/RANTES (DRN00B)(99)

We have publications tested in 6 confirmed species: Human, Mouse, Rat, Primate, Primate - Macaca mulatta (Rhesus Macaque), Primate - Pan troglodytes (Chimpanzee).

Filter By Application
All Applications
Filter By Species
Primate - Macaca mulatta (Rhesus Macaque)
Primate - Pan troglodytes (Chimpanzee)
All Species
Showing Publications 1 - 10 of 99. Show All 99 Publications.
Publications using DRN00B Applications Species
Ka, NL;Park, MK;Kim, SS;Jeon, Y;Hwang, S;Kim, SM;Lim, GY;Lee, H;Lee, MO; NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling Cancer research 2023-07-03 [PMID: 37395684] (Human) Human
SS Withers, CE Moeller, CN Quick, CC Liu, SM Baham, JS Looper, R Subramania, KG Kousoulas Effect of stimulator of interferon genes (STING) signaling on radiation-induced chemokine expression in human osteosarcoma cells PLoS ONE, 2023-04-20;18(4):e0284645. 2023-04-20 [PMID: 37079538] (Human) Human
SS Withers, CE Moeller, CN Quick, CC Liu, SM Baham, JS Looper, R Subramania, KG Kousoulas Effect of stimulator of interferon genes (STING) signaling on radiation-induced chemokine expression in human osteosarcoma cells PLoS ONE, 2023;18(4):e0284645. 2023 [PMID: 37079538] (Human) Human
RO Ali, GM Quinn, R Umarova, JA Haddad, GY Zhang, EC Townsend, L Scheuing, KL Hill, M Gewirtz, S Rampertaap, SD Rosenzweig, AT Remaley, JM Han, V Periwal, H Cai, PJ Walter, C Koh, EB Levy, DE Kleiner, O Etzion, T Heller Longitudinal multi-omics analyses of the gut-liver axis reveals metabolic dysregulation in hepatitis C infection and cirrhosis Nature Microbiology, 2022-12-15;0(0):. 2022-12-15 [PMID: 36522461] (Human) Human
FJ Julián-Vil, M Serrano-Po, E Ramalle-Gó, A Martínez, L Ochoa-Call CCL5 Levels Predict Stroke Volume Growth in Acute Ischemic Stroke and Significantly Diminish in Hemorrhagic Stroke Patients International Journal of Molecular Sciences, 2022-09-01;23(17):. 2022-09-01 [PMID: 36077361] (Human) Human
J Baran, ? Niewiara, J Podolec, M Siedli?ski, E Józefczuk, A Bernacik, R Badacz, T Przew?ocki, P Pieni??ek, K ?mudka, J Legutko, A Kab?ak-Zie Serum and Vascular Stiffness Biomarkers Associated with the Severity of Degenerative Aortic Valve Stenosis and Cardiovascular Outcomes Oncogene, 2022-06-17;9(6):. 2022-06-17 [PMID: 35735822] (Human) Human
N Lin, L Chen, Y Zhang, Y Yang, L Zhang, L Chen, P Zhang, H Su, M Yin KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment Scientific Reports, 2022-04-10;12(1):6015. 2022-04-10 [PMID: 35399116] (Human) Human
NL Ka, GY Lim, S Hwang, SS Kim, MO Lee IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer Cell Reports, 2021-12-21;37(12):110138. 2021-12-21 [PMID: 34936865] (Human) Human
RV Uzhachenko, V Bharti, Z Ouyang, A Blevins, S Mont, N Saleh, HA Lawrence, C Shen, SC Chen, GD Ayers, DG DeNardo, C Arteaga, A Richmond, AE Vilgelm Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T�cells into mammary tumors Cell Reports, 2021-04-06;35(1):108944. 2021-04-06 [PMID: 33826903] (Human) Human
Show All 99 Publications.

Reviews for CCL5/RANTES (DRN00B) (0)

There are no reviews for CCL5/RANTES (DRN00B). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for CCL5/RANTES (DRN00B) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional CCL5/RANTES Products

Blogs on CCL5/RANTES

There are no specific blogs for CCL5/RANTES, but you can read our latest blog posts.

Contact Information

Product PDFs

Review this Product

Be the first to review our Human CCL5/RANTES Quantikine ELISA Kit and receive a gift card or discount.


Gene Symbol CCL5